CD226 and neoplasm: Further emphasizing the potential interaction among diverse costimulatory and inhibitory pathways are observations from preclinical studies demonstrating that efficacy of anti-CD137, anti-GITR, and anti-CTLA-4 required CD226 for anti-tumor activity (Wang et al., 2018; Weulersse et al., 2020).